Franklin, TN – July 21, 2026 – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the appointment of Paul Pagano, PhD, as Chief of Medical Affairs. In this role, Dr. Pagano will bridge scientific development and commercialization, helping to shape the strategic vision for clinical application of the Company’s transplant diagnostics. He will focus on advancing evidence generation strategies, strengthening medical and scientific communications, and deepening engagement with clinical and academic experts to support the continued adoption and evolution of Verici Dx’s solutions.
“Paul brings an important combination of deep scientific expertise and proven leadership in building and scaling diagnostic organizations,” said Sara Barrington, Chief Executive Officer of Verici Dx. “His experience translating complex science into clinically meaningful products will be invaluable as we continue to expand the impact of our transplant diagnostics portfolio and support clinicians in improving patient outcomes.”
Dr. Pagano has over 20 years of experience across chemistry, engineering, and precision diagnostics. Trained at UCLA in translational research, he has authored multiple publications covering directed evolution, microfluidic lab-on-chip technology, resistance mechanisms in targeted cancer therapy, and early disease detection strategies. Most recently, he served as Chief Executive Officer and Chief Scientific Officer at LungLife AI (LON: LLAI), where he led the development and commercial launch of a best-in-class early lung cancer detection product that was subsequently licensed by a leading liquid biopsy company.
Dr. Pagano earned a BS in Microbiology and Immunology from UC Santa Barbara and a PhD in Pharmacology from the David Geffen School of Medicine at UCLA.
“I am excited to join Verici Dx at a time of impressive growth and continued advancement of its transplant diagnostics portfolio,” said Dr. Pagano. “My goal has always been to drive innovation in healthcare that makes a meaningful impact on patient care, and at Verici Dx I see that happening today. I look forward to working with the team to further strengthen the clinical evidence base and expand the reach of these important diagnostics.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.
